18155-Lymphomas-NA-108

Lymphomas

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

  • Details

ClinicalTrials.gov ID: NCT03734016
Diagnosis Type: NA
USOR Number:

  • Address

7777 Forest Lane, Suite D400
Dallas, TX 75230
P: (972) 566-6647

Search by practice name, trial titles, indicators and specific disease types.